Overview

Description

  • NatureSynthetic
  • Amino Acid Sequence
    • SpeciesHuman
    • SequenceRQSLQQSMPPCEPP
    • Amino acids1416 to 1429

Associated products

Specifications

Our Abpromise guarantee covers the use of ab23056 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-MLH3 antibody (ab4834)

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

General Info

  • Alternative names
    • DNA mismatch repair protein Mlh3
    • HNPCC
    • HNPCC 7
    • HNPCC7
    • MGC138372
    • Mismatch repair gene MLH 3
    • Mismatch repair gene MLH3
    • MLH 3
    • MLH3
    • MLH3_HUMAN
    • MutL homolog 3
    • MutL homolog 3 (E. coli)
    • MutL protein homolog 3
    • S240II117
    see all
  • FunctionProbably involved in the repair of mismatches in DNA.
  • Tissue specificityUbiquitous.
  • Involvement in diseaseDefects in MLH3 are the cause of hereditary non-polyposis colorectal cancer type 7 (HNPCC7) [MIM:614385]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
    Defects in MLH3 are a cause of colorectal cancer (CRC) [MIM:114500].
  • Sequence similaritiesBelongs to the DNA mismatch repair mutL/hexB family.
  • Cellular localizationNucleus.
  • Information by UniProt

References for Human MLH3 peptide (ab23056)

ab23056 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab23056.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"